# US 2004/0082026 A1 · Interferon alpha: remodeling and glycoconjugation of interferon alpha

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082026 A1
- Document ID: US20040082026A1
- Status: Published application
- Kind: A1
- Application number: 10/411,049
- Filed: 2003-04-09
- Published: 2004-04-29
- Earliest claimed: 2001-10-10
- Assignees: Neose Technologies, Inc.
- Inventors: Shawn DeFrees; David Zopf; Robert Bayer; Caryn Bowe; David Hakes; Xi Chen
- Web page: https://patentgrep.com/patent/US20040082026A1

## CPC

- C07K 1/006: {of peptides containing derivatised side chain amino acids}
- C07K 1/1077: {by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids}
- C07K 1/13: Labelling of peptides
- C07K 9/00: Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K 14/505: Erythropoietin [EPO]
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention includes a multitude of methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

## Claims

### Claim 1

A cell-free, in vitro method of remodeling an interferon alpha peptide, said peptide having the formula:
149
wherein
AA is a terminal or internal amino acid residue of said peptide;
X1-X2 is a saccharide covalently linked to said AA, wherein
X1 is a first glycosyl residue; and
X2 is a second glycosyl residue covalently linked to X1, wherein X1 and X2 are selected from monosaccharyl and oligosaccharyl residues;
said method comprising:
(a) removing X2 or a saccharyl subunit thereof from said peptide, thereby forming a truncated glycan; and
(b) contacting said truncated glycan with at least one glycosyltransferase and at least one glycosyl donor under conditions suitable to transfer said at least one glycosyl donor to said truncated glycan, thereby remodeling said interferon alpha peptide.

### Claim 2 (depends on 1)

The method of claim 1, further comprising:
(c) removing X1, thereby exposing said AA; and
(d) contacting said AA with at least one glycosyltransferase and at least one glycosyl donor under conditions suitable to transfer said at least one glycosyl donor to said AA, thereby remodeling said interferon alpha peptide.

### Claim 3 (depends on 1)

The method of claim 1, further comprising:
(e) prior to step (b), removing a group added to said saccharide during post-translational modification.

### Claim 4 (depends on 3)

The method of claim 3, wherein said group is a member selected from phosphate, sulfate, carboxylate and esters thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein said peptide has the formula:
150
wherein
Z is a member selected from O, S, NH or a crosslinker.

### Claim 6 (depends on 1)

The method of claim 1, wherein at least one of said glycosyl donors comprises a modifying group.

### Claim 7 (depends on 1)

The method of claim 1, wherein said modifying group is a member selected from the group consisting of a polymer, a therapeutic moiety, a detectable label, a reactive linker group, a targeting moiety, and a peptide.

### Claim 8 (depends on 7)

The method of claim 7, wherein said modifying group is a water soluble polymer.

### Claim 9 (depends on 8)

The method of claim 8, wherein said water soluble polymer comprises poly(ethylene glycol).

### Claim 10 (depends on 9)

The method of claim 9, wherein said poly(ethylene glycol) has a molecular weight distribution that is essentially homodisperse.

### Claim 11

A cell-free in vitro method of remodeling an interferon alpha peptide, said peptide having the formula:
151
wherein
X3, X4, X5, X6, X7, and X17 are independently selected monosaccharyl or oligosaccharyl residues; and
a, b, c, d, e and x are independently selected from the integers 0, 1 and 2, with the proviso that at least one member selected from a, b, c, d, and e and x are 1 or 2; said method comprising:
(a) removing at least one of X3, X4, X5, X6, X7, or X17, a saccharyl subunit thereof from said peptide, thereby forming a truncated glycan; and
(b) contacting said truncated glycan with at least one glycosyltransferase and at least one glycosyl donor under conditions suitable to transfer said at least one glycosyl donor to said truncated glycan, thereby remodeling said interferon alpha peptide.

### Claim 12 (depends on 11)

The method of claim 11, wherein said removing of step (a) produces a truncated glycan in which a, b, c, e and x are each 0.

### Claim 13 (depends on 11)

The method of claim 11, wherein X3, X5 and X7 are selected from the group consisting of (mannose), and (mannose)z-(X8)y
wherein
X8 is a glycosyl moiety selected from mono- and oligo-saccharides;
y is an integer selected from 0 and 1; and
z is an integer between 1 and 20, wherein
when z is 3 or greater, (mannose)z is selected from linear and branched structures.

### Claim 14 (depends on 11)

The method of claim 11, wherein X4 is selected from the group consisting of GlcNAc and xylose.

### Claim 15 (depends on 11)

The method of claim 11, wherein X3, X5 and X7 are (mannose)u, wherein u is selected from the integers between 1 and 20, and when u is 3 or greater, (mannose)u is selected from linear and branched structures.

### Claim 16 (depends on 11)

The method of claim 11, wherein at least one of said glycosyl donors comprises a modifying group.

### Claim 17 (depends on 16)

The method of claim 16, wherein said modifying group is a member selected from the group consisting of a polymer, a therapeutic moiety, a detectable label, a reactive linker group, a targeting moiety, and a peptide.

### Claim 18 (depends on 17)

The method of claim 17 wherein said modifying group is a water soluble polymer.

### Claim 19 (depends on 18)

The method of claim 18, wherein said water soluble polymer comprises poly(ethylene glycol).

### Claim 20 (depends on 19)

The method of claim 19, wherein said poly(ethylene glycol) has a molecular weight distribution that is essentially homodisperse.

### Claim 21

A cell-free in vitro method of remodeling an interferon alpha peptide comprising a glycan having the formula:
152
wherein
r, s, and t are integers independently selected from 0 and 1, said method comprising:
(a) contacting said peptide with at least one glycosyltransferase and at least one glycosyl donor under conditions suitable to transfer said at least one glycosyl donor to said glycan, thereby remodeling said interferon alpha peptide.

### Claim 22 (depends on 21)

The method of claim 21, wherein at least one of said glycosyl donors comprises a modifying group.

### Claim 23 (depends on 22)

The method of claim 22, wherein said modifying group is a member selected from the group consisting of a polymer, a therapeutic moiety, a detectable label, a reactive linker group, a targeting moiety, and a peptide.

### Claim 24 (depends on 23)

The method of claim 23 wherein said modifying group is a water soluble polymer.

### Claim 25 (depends on 24)

The method of claim 24, wherein said water soluble polymer comprises poly(ethylene glycol).

### Claim 26 (depends on 25)

The method of claim 25, wherein said poly(ethylene glycol) has a molecular weight distribution that is essentially homodisperse.

### Claim 27 (depends on 1)

The method of claim 1, wherein said peptide has the formula:
153
wherein
X9 and X10 are independently selected monosaccharyl or oligosaccharyl residues; and
m, n and f are integers selected from 0 and 1.

### Claim 28 (depends on 1)

The method of claim 1, wherein said peptide has the formula:
154
wherein
X11 and X12 are independently selected glycosyl moieties; and
r and x are integers independently selected from 0 and 1.

### Claim 29 (depends on 28)

The method of claim 28, wherein X11 and X12 are (mannose)q, wherein
q is selected from the integers between 1 and 20, and when q is three or greater (mannose)q is selected from linear and branched structures.

### Claim 30 (depends on 1)

The method of claim 1, wherein said peptide has the formula:
155
wherein
X13, X14, and X15 are independently selected glycosyl residues; and
g, h, i, j, k, and p are independently selected from the integers 0 and 1, with the proviso that at least one of g, h, i, j, k and p is 1.

### Claim 31 (depends on 30)

The method of claim 30, wherein
X14 and X15 are members independently selected from GlcNAc and Sia; and i and k are independently selected from the integers 0 and 1, with the proviso that at least one of i and k is 1, and when k is 1, g, h, and j are 0.

### Claim 32 (depends on 1)

The method of claim 1, wherein said peptide has the formula:
156
wherein
X16 is a member selected from:
157
wherein
s and i are integers independently selected from 0 and 1.

### Claim 33 (depends on 1)

The method of claim 1, wherein said removing utilizes a glycosidase.

### Claim 34

A cell-free, in vitro method of remodeling an interferon alpha peptide having the formula:
158
wherein
AA is a terminal or internal amino acid residue of said peptide;
X1 is a glycosyl residue covalently linked to said AA, selected from monosaccharyl and oligosaccharyl residues; and
u is an integer selected from 0 and 1, said method comprising:
contacting said peptide with at least one glycosyltransferase and at least one glycosyl donor under conditions suitable to transfer said at least one glycosyl donor to said truncated glycan, wherein said glycosyl donor comprises a modifying group, thereby remodeling said interferon alpha peptide.

### Claim 35 (depends on 34)

The method of claim 34, wherein said modifying group is a member selected from the group consisting of a polymer, a therapeutic moiety, a detectable label, a reactive linker group, a targeting moiety, and a peptide.

### Claim 36 (depends on 35)

The method of claim 35 wherein said modifying group is a water soluble polymer.

### Claim 37 (depends on 36)

The method of claim 36, wherein said water soluble polymer comprises poly(ethylene glycol).

### Claim 38 (depends on 37)

The method of claim 37, wherein said poly(ethylene glycol) has a molecular weight distribution that is essentially homodisperse.

### Claim 39

A covalent conjugate between an interferon alpha peptide and a modifying group that alters a property of said peptide, wherein said modifying group is covalently attached to said peptide at a preselected glycosyl or amino acid residue of said peptide via an intact glycosyl linking group.

### Claim 40 (depends on 39)

The covalent conjugate of claim 39, wherein said modifying group is a member selected from the group consisting of a polymer, a therapeutic moiety, a detectable label, a reactive linker group, a targeting moiety, and a peptide.

### Claim 41 (depends on 39)

The covalent conjugate of claim 39, wherein said modifying group and an intact glycosyl linking group precursor are linked as a covalently attached unit to said peptide via the action of an enzyme, said enzyme converting said precursor to said intact glycosyl linking group, thereby forming said conjugate.

### Claim 42 (depends on 39)

The covalent conjugate of claim 39 comprising:
a first modifying group covalently linked to a first residue of said peptide via a first intact glycosyl linking group, and
a second glycosyl linking group linked to a second residue of said peptide via a second intact glycosyl linking group.

### Claim 43 (depends on 42)

The covalent conjugate of claim 42, wherein said first residue and said second residue are structurally identical.

### Claim 44 (depends on 42)

The covalent conjugate of claim 42, wherein said first residue and said second residue have different structures.

### Claim 45 (depends on 42)

The covalent conjugate of claim 42 wherein said first residue and said second residue are glycosyl residues.

### Claim 46 (depends on 42)

The covalent conjugate of claim 42, wherein said first residue and said second residue are amino acid residues.

### Claim 47 (depends on 39)

The covalent conjugate of claim 39, wherein said peptide is remodeled prior to forming said conjugate.

### Claim 48 (depends on 47)

The covalent conjugate of claim 47, wherein the remodeled peptide is remodeled to introduce an acceptor moiety for said intact glycosyl linking group.

### Claim 49 (depends on 39)

The covalent conjugate of claim 39, wherein said modifying group is a water-soluble polymer.

### Claim 50 (depends on 49)

The covalent conjugate of claim 49, wherein said water-soluble polymer comprises poly(ethylene glycol).

### Claim 51 (depends on 39)

The covalent conjugate of claim 39, wherein said intact glycosyl linking unit is a member selected from the group consisting of a sialic acid residue, a Gal residue, a GlcNAc residue and a GalNAc residue.

### Claim 52 (depends on 50)

The covalent conjugate of claim 50, wherein said poly(ethylene glycol) has a molecular weight distribution that is essentially homodisperse.

### Claim 53

A method of forming a covalent conjugate between a polymer and a glycosylated or non-glycosylated peptide, wherein said polymer is conjugated to said peptide via an intact glycosyl linking group interposed between and covalently linked to both said peptide and said polymer, said method comprising:
contacting said peptide with a mixture comprising a nucleotide sugar covalently linked to said polymer and a glycosyltransferase for which said nucleotide sugar is a substrate under conditions sufficient to form said conjugate, wherein said peptide is interferon alpha.

### Claim 54 (depends on 53)

The method of claim 53, wherein said polymer is a water-soluble polymer.

### Claim 55 (depends on 53)

The method of claim 53, wherein said glycosyl linking group is covalently attached to a glycosyl residue covalently attached to said peptide.

### Claim 56 (depends on 53)

The method of claim 53, wherein said glycosyl linking group is covalently attached to an amino acid residue of said peptide.

### Claim 57 (depends on 53)

The method of claim 53, wherein said polymer comprises a member selected from the group consisting of a polyalkylene oxide and a polypeptide.

### Claim 58 (depends on 57)

The method of claim 57, wherein said polyalkylene oxide is poly(ethylene glycol).

### Claim 59 (depends on 58)

The method of claim 58, wherein said poly(ethylene glycol) has a degree of polymerization of from about 1 to about 20,000.

### Claim 60 (depends on 59)

The method of claim 59, wherein said polyethylene glycol has a degree of polymerization of from about 1 to about 5,000.

### Claim 61 (depends on 60)

The method of claim 60, wherein said polyethylene glycol has a degree of polymerization of from about 1 to about 1,000.

### Claim 62 (depends on 53)

The method of claim 53, wherein said glycosyltransferase is selected from the group consisting of sialyltransferase, galactosyltransferase, glucosyltransferase, GalNAc transferase, GlcNAc transferase, fucosyltransferase, and mannosyltransferase.

### Claim 63 (depends on 53)

The method of claim 53, wherein said glycosyltransferase is recombinantly produced.

### Claim 64 (depends on 63)

The method of claim 63, wherein said glycosyltransferase is a recombinant prokaryotic enzyme.

### Claim 65 (depends on 63)

The method of claim 63, wherein said glycosyltransferase is a recombinant eukaryotic enzyme.

### Claim 66 (depends on 53)

The method of claim 53, wherein said nucleotide sugar is selected from the group consisting of UDP-glycoside, CMP-glycoside, and GDP-glycoside.

### Claim 67 (depends on 66)

The method of claim 66, wherein said nucleotide sugar is selected from the group consisting of UDP-galactose, UDP-galactosamine, UDP-glucose, UDP-glucosamine, UDP-N-acetylgalactosamine, UDP-N-acetylglucosamine, GDP-mannose, GDP-fucose, CMP-sialic acid, CMP-NeuAc.

### Claim 68 (depends on 53)

The method of claim 53, wherein said glycosylated peptide is partially deglycosylated prior to said contacting.

### Claim 69 (depends on 53)

The method of claim 53, wherein said intact glycosyl linking group is a sialic acid residue.

### Claim 70 (depends on 53)

The method of claim 53, wherein said method is performed in a cell-free environment.

### Claim 71 (depends on 53)

The method of claim 53, wherein said covalent conjugate is isolated.

### Claim 72 (depends on 71)

The method of claim 71, wherein said covalent conjugate is isolated by membrane filtration.

### Claim 73

A composition for forming a conjugate between a peptide and a modified sugar, said composition comprising: an admixture of a modified sugar, a glycosyltransferase, and a peptide acceptor substrate, wherein said modified sugar has covalently attached thereto a member selected from a polymer, a therapeutic moiety and a biomolecule, wherein said peptide is interferon alpha.

### Claim 74 (depends on 1)

An interferon alpha peptide remodeled by the method of claim 1.

### Claim 75 (depends on 74)

A pharmaceutical composition comprising the interferon alpha peptide of claim 74.

### Claim 76 (depends on 11)

An interferon alpha peptide remodeled by the method of claim 11.

### Claim 77 (depends on 76)

A pharmaceutical composition comprising the interferon alpha peptide of claim 76.

### Claim 78 (depends on 21)

A interferon alpha peptide remodeled by the method of claim 21.

### Claim 79 (depends on 78)

A pharmaceutical composition comprising the interferon alpha peptide of claim 78.

### Claim 80 (depends on 27)

An interferon alpha peptide remodeled by the method of claim 27.

### Claim 81 (depends on 80)

A pharmaceutical composition comprising the interferon alpha peptide of claim 80.

### Claim 82 (depends on 28)

An interferon alpha peptide remodeled by the method of claim 28.

### Claim 83 (depends on 82)

A pharmaceutical composition comprising the interferon alpha peptide of claim 82.

### Claim 84 (depends on 34)

An interferon alpha peptide remodeled by the method of claim 34.

### Claim 85 (depends on 84)

A pharmaceutical composition comprising the interferon alpha peptide of claim 84.

### Claim 86

A cell-free, in vitro method of remodeling a peptide having the formula:
159
wherein
AA is a terminal or internal amino acid residue of said peptide, said method comprising:
contacting said peptide with at least one glycosyltransferase and at least one glycosyl donor under conditions suitable to transfer said at least one glycosyl donor to said amino acid residue, wherein said glycosyl donor comprises a modifying group, thereby remodeling said peptide, wherein said peptide is interferon alpha.

### Claim 87

A method of forming a conjugate between an interferon alpha peptide and a modifying group, wherein said modifying group is covalently attached to said glycopeptide through an intact glycosyl linking group, said glycopeptide comprising a glycosyl residue having a formula selected from:
160
wherein
a, b, c, d, i, n, o, p, q, r, s, t, u, aa, bb, cc, dd, and ee are members independently selected from 0 and 1;
e, f, g, and h are members independently selected from the integers from 0 to 6;
j, k, l, and m are members independently selected from the integers from 0 to 20;
v, w, x, y, and z are 0; and
R is a modifying group, a mannose or an oligomannose
R′ is H, a glycosyl residue, a modifying group, or a glycoconjugate, said method comprising:
(a) contacting said glycopeptide with a member selected from a glycosyltransferase, an GalNAc transferase operating synthetically and a sialyltransferase, and a modified glycosyl donor, comprising a glycosyl moiety which is a substrate for said glycosyltransferase covalently linked to said modifying group, under conditions appropriate for the formation of said intact glycosyl linking group.

### Claim 88 (depends on 87)

The method of claim 87, further comprising:
(b) prior to step (a), contacting said glycopeptide with a sialidase under conditions appropriate to remove sialic acid from said glycopeptide.

### Claim 89 (depends on 87)

The method of claim 87, further comprising:
(c) contacting the product from step (a) with a moiety that reacts with said modifying group, thereby forming a conjugate between said intact glycosyl linking group and said moiety.

### Claim 90 (depends on 87)

The method of claim 87, further comprising:
(d) prior to step (a) contacting said glycopeptide with a combination of a glycosidase and a sialidase.

### Claim 91 (depends on 87)

The method of claim 87, further comprising:
(e) prior to step (a), contacting said glycopeptide with an endoglycanase under conditions appropriate to cleave a glycosyl moiety from said glycopeptide.

### Claim 92 (depends on 87)

The method of claim 87, further comprising:
(f) prior to step (a), contacting said glycopeptide with N-acetylglucosamine transferase and a GlcNAc donor under conditions appropriate to transfer GlcNAc to said glycopeptide.

### Claim 93 (depends on 87)

The method of claim 87, further comprising:
(g) prior to step (a), contacting said glycopeptide with a galactosyl transferase and a galactose donor under conditions appropriate to transfer galactose to said product.

### Claim 94 (depends on 87)

The method of claim 87, further comprising:
(h) prior to step (b), contacting said glycopeptide with endoglycanase under conditions appropriate to cleave a glycosyl moiety from said glycopeptide.

### Claim 95 (depends on 87)

The method of claim 87, further comprising:
(i) prior to step (a), contacting said glycopeptide with a mannosidase under conditions appropriate to remove mannose from said glycopeptide.

### Claim 96 (depends on 87)

The method of claim 87, further comprising:
(j) contacting the product of step (a) with a sialyltransferase and a sialic acid donor under conditions appropriate to transfer sialic acid to said product.

### Claim 97 (depends on 87)

The method of claim 87, wherein said modifying group is a member selected from a polymer, a toxin, a radioisotope, a therapeutic moiety and a glycoconjugate.

### Claim 98 (depends on 87)

The method of claim 87, wherein
a, b, c, d, aa, and bb are 1;
e, f, g, and h are members independently selected from the integers from 1 to 4;
i, j, k, l, m, r, s, t, u, and cc are members independently selected from 0 and 1; and
n, o, p, q, v, w, x, y, z, dd, and ee are 0.

### Claim 99 (depends on 87)

The method of claim 87, wherein
a, b, c, d, f, h, j, k, l, m, n, o, p, q, s, u, v, w, x, y, z, cc, dd, and ee are 0;
e, g, i, r, and t are members independently selected from 0 and 1; and
aa and bb are 1.

### Claim 100 (depends on 87)

The method of claim 87, wherein
a, b, c, d, e, f, g, i, j, k, l, m, r, s, t, and u are members independently selected from 0 and 1;
h is a member independently selected from the integers from 1 to 3;
dd, v, w, x, and y are 0; and
aa and bb are 1.

### Claim 101 (depends on 87)

The method of claim 87, wherein
a, b, c, d, f, h, j, k, l, m, s, u, v, w, x, y, and dd are 0;
e, g, i, r, and t are members independently selected from 0 and 1; and
aa and bb are 1.

### Claim 102 (depends on 87)

The method of claim 87, wherein
a, b, c, d, e, f, g, h, i, j, k, l, m, and dd are 0;
r, s, t, u, v, w, x, and y are members independently selected from 0 and 1; and
aa and bb are 1.

### Claim 103 (depends on 87)

The method of claim 87, wherein
a, b, c, d, e, f, g, h, i, r, s, t, and u are members independently selected from 0 and 1;
j, k, l, m, v, w, x, y, and dd are 0; and
aa and bb are 1.

### Claim 104 (depends on 87)

The method of claim 87, wherein
a, b, c, d, e, f, g, i, j, k, l, m, r, s, t, and u are members independently selected from 0 and 1;
h is a member independently selected from the integers from 1 to 3;
v, w, x, y, and dd are 0; and
aa and bb are 1.

### Claim 105 (depends on 87)

The method of claim 87, wherein
a, b, c, d, f, h, j, k, l, m, s, u, v, w, x, y, and dd are 0;
e, g, i, r, and t are members independently selected from 0 and 1; and
aa and bb are 1.

### Claim 106 (depends on 87)

The method of claim 87, wherein
n, o, and p are members independently selected from 0 and 1;
q is 1; and
z, cc, and ee are 0.

### Claim 107 (depends on 87)

The method of claim 87, wherein
n and q are members independently selected from 0 and 1; and
o, p, z, cc, and ee are 0.

### Claim 108 (depends on 87)

The method of claim 87, wherein
n is 0 or 1;
q is 1; and
o, p, z, cc, and ee are 0.

### Claim 109 (depends on 87)

The method of claim 87, wherein
n, o, p, and f are members independently selected from 0 and 1;
q is 1; and
z and ee are 0.

### Claim 110 (depends on 87)

The method of claim 87, wherein
n, o, p, and q are members independently selected from 0 and 1; and
z, cc, and ee are 0.

### Claim 111 (depends on 87)

The method of claim 87, wherein
n and q are members independently selected from 0 and 1; and
o, p, z, cc, and ee are 0.

### Claim 112 (depends on 87)

The method of claim 87, wherein
n, o, p, q, z, cc, and ee are 0.

### Claim 113 (depends on 87)

An interferon alpha peptide conjugate formed by the method of claim 87.

### Claim 114

An interferon alpha peptide comprising one or more glycans, having a glycoconjugate molecule covalently attached to said peptide.

### Claim 115 (depends on 114)

The interferon alpha peptide of claim 114, wherein said one or more glycans is a monoantennary glycan.

### Claim 116 (depends on 114)

The interferon alpha peptide of claim 114, wherein said one or more glycans is a biantennary glycan.

### Claim 117 (depends on 114)

The interferon alpha peptide of claim 114, wherein said one or more glycans is a triantennary glycan.

### Claim 118 (depends on 114)

The interferon alpha peptide of claim 114, wherein said one or more glycans is at least a triantennary glycan.

### Claim 119 (depends on 114)

The interferon alpha peptide of claim 114, wherein said one or more glycans comprises at least two glycans comprising a mixture of mono or multiantennary glycans.

### Claim 120 (depends on 114)

The interferon alpha peptide of claim 114, wherein said one or more glycans is selected from an N-linked glycan and an O-linked glycan.

### Claim 121 (depends on 114)

The interferon alpha peptide of claim 114, wherein said one or more glycans is at least two glycans selected from an N-linked and an O-linked glycan.

### Claim 122 (depends on 114)

The interferon alpha peptide of claim 114, wherein said peptide is expressed in a cell selected from the group consisting of a prokaryotic cell and a eukaryotic cell.

### Claim 123 (depends on 122)

The interferon alpha peptide of claim 122, wherein said eukaryotic cell is selected from the group consisting of a mammalian cell, an insect cell and a yeast cell.

### Claim 124

A method of treating a mammal having hepatitis C, said method comprising administering to said mammal an interferon alpha peptide having one or more glycans having a glycoconjugate molecule attached to said peptide.

### Claim 125 (depends on 124)

The method of claim 124, wherein said glycoconjugate is poly(ethylene glycol).

### Claim 126 (depends on 124)

The method of claim 124, wherein said mammal is a human.
